529 related articles for article (PubMed ID: 25050456)
21. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Ballmann M; Smyth A; Geller DE
Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
[TBL] [Abstract][Full Text] [Related]
22. [Antibiotic inhalation in cystic fibrosis. A review of the literature].
Steinkamp G
Monatsschr Kinderheilkd; 1991 Feb; 139(2):73-80. PubMed ID: 1903843
[TBL] [Abstract][Full Text] [Related]
23. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Langan KM; Kotsimbos T; Peleg AY
Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
[TBL] [Abstract][Full Text] [Related]
24. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
[TBL] [Abstract][Full Text] [Related]
25. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
Wilson R; Welte T; Polverino E; De Soyza A; Greville H; O'Donnell A; Alder J; Reimnitz P; Hampel B
Eur Respir J; 2013 May; 41(5):1107-15. PubMed ID: 23018904
[TBL] [Abstract][Full Text] [Related]
26. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Aksamit T; De Soyza A; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371384
[TBL] [Abstract][Full Text] [Related]
27. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
Aksamit T; Bandel TJ; Criollo M; De Soyza A; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
Contemp Clin Trials; 2017 Jul; 58():78-85. PubMed ID: 28495619
[TBL] [Abstract][Full Text] [Related]
28. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
[TBL] [Abstract][Full Text] [Related]
29. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
31. Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis.
Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Patzlaff A; Weimann B
J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):156-163. PubMed ID: 30848695
[No Abstract] [Full Text] [Related]
32. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
Bilton D; Henig N; Morrissey B; Gotfried M
Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
[TBL] [Abstract][Full Text] [Related]
34. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
35. [Ciprofloxacin: an alternative oral treatment in respiratory Pseudomonas infection in cystic fibrosis].
Magni A; Pradal U; Cazzola G; Mastella G
Pediatr Med Chir; 1990; 12(5):531-4. PubMed ID: 2087426
[TBL] [Abstract][Full Text] [Related]
36. Eradication of Pseudomonas aeruginosa in cystic fibrosis.
Eber E; Thalhammer GH; Zach MS
Eur Respir J; 2006 Feb; 27(2):438-9. PubMed ID: 16452606
[No Abstract] [Full Text] [Related]
37. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
38. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Somayaji R; Parkins MD
Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
[TBL] [Abstract][Full Text] [Related]
39. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Adi H; Young PM; Chan HK; Agus H; Traini D
Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
[TBL] [Abstract][Full Text] [Related]
40. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
